Prognostic value of the S100B protein in newly diagnosed and recurrent glioma patients: a serial analysis
Prognostic value of the S100B protein in newly diagnosed and recurrent glioma patients: a serial analysis
复制标题
DOI：
10.1007/s11060-016-2204-z
复制
发表时间：
2016-09-01
影响因子：
3.9
通讯作者：
Heimans, J. J.
中科院分区：
文献类型：
--
作者：
Holla, F. K.;Postma, T. J.;Heimans, J. J.
S100B蛋白与脑损伤和血脑屏障的破坏有关。先前的一项初步研究表明，血清S100B水平高与胶质瘤患者的生存时间较短有关。我们研究的目的是评估血清S100B对初诊和复发的胶质瘤患者的生存率和纵向动态的预后价值。我们在化疗开始前(基线)和替莫唑胺化疗期间的固定时间点采集了新诊断和复发的胶质瘤患者的血样。S100B-数据按参考值上限0.1mug/L进行二分法，总体生存(OS)用Kaplan-Meier曲线估计，组间比较采用对数秩次分析。为了纠正潜在的混杂因素，使用了COX回归分析。我们包括86例新诊断的患者和27例复发的胶质瘤患者。两组中的大多数患者的基线血清水平都在正常范围内。在新诊断的患者中，我们发现基线S100B水平和GT；0.1mU/L水平的患者与<；0.1mU/L的患者相比，OS无显着差异。在复发的胶质瘤患者中，我们发现S100B水平升高的患者OS明显缩短。在两组患者中，S100B值在整个病程中没有显著变化。在新诊断的胶质瘤患者中，血清S100B水平似乎没有预后价值。在复发的胶质瘤患者中，S100B可能在预后方面有价值。
The S100B protein is associated with brain damage and a breached blood-brain barrier. A previous pilot study showed that high serum levels of S100B are associated with shorter survival in glioma patients. The aim of our study was to assess the prognostic value in terms of survival and longitudinal dynamics of serum S100B for patients with newly diagnosed and recurrent glioma. We obtained blood samples from patients with newly diagnosed and recurrent glioma before the start (baseline) and at fixed time-points during temozolomide chemotherapy. S100B-data were dichotomized according to the upper limit of the reference value of 0.1 mu g/L. Overall survival (OS) was estimated with Kaplan-Meier curves and groups were compared with the log rank analysis. To correct for potential confounders a Cox regression analysis was used. We included 86 patients with newly-diagnosed and 27 patients with recurrent glioma. Most patients in both groups had baseline serum levels within normal limits. In the newly diagnosed patients we found no significant difference in OS between the group of patients with S100B levels > 0.1 mu g/L at baseline compared to those with < 0.1 mu g/L. In the patients with recurrent glioma we found a significantly shorter OS for patients with raised levels. In both groups, S100B values did not change significantly throughout the course of the disease. Serum S100B levels do not seem to have prognostic value in newly diagnosed glioma patients. In recurrent glioma patients S100B might be of value in terms of prognostication of survival.